London, UK, 19 December 2017 - Trends and truth in life science investment is the latest annual report, published by our partner Biotech and Money, to offer unique and actionable insight into investor attitudes, biases and preferences in healthcare opportunities in Europe.
The perception report provides unique and powerful investor intelligence from across the investment community, including M&A expectations, investment trends and investment risks. At the same time, the survey reviews several myths and attitudes assumed to be common in the sector.
Neil Darkes, Co-CEO at Biotech and Money, said: “We believe the report continues to provide a timely and credible source of both qualitative and quantitative insight into the investment habits and mandates of some of the industry’s most active healthcare and life science investors. We’re delighted to be releasing the 2nd edition to further help inform the decisions and strategies of the sector’s professionals.”
The report launch will be a key feature at the 600-person, 4th annual Biotech and Money/Medtech and Money World Congress on 5-6 February at 200 Aldersgate, St Paul’s, London and made available exclusively to all attendees for free.
To find out more, visit http://biotechandmoney.com/world-congress
About Biotech and Money
Biotech and Money is an influential community of senior life science decision makers. Through our impactful events, powerful thought leadership content and unique networking opportunities, we exist to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.. Visit www.biotechandmoney.com.
For media information please contact Ewa Campbell at firstname.lastname@example.org. Alternatively call on +44 (0) 203 6375 908.